Topic
Yizhi capsule
About: Yizhi capsule is a research topic. Over the lifetime, 10 publications have been published within this topic receiving 42 citations.
Papers
TL;DR: There is no evidence from randomised controlled trials to support or proscribe against the use of 'Yizhi capsule' as a treatment for vascular dementia.
Abstract: Background Vascular dementia (VD) is a syndrome or diagnosis that has different causes and clinical manifestations relating to several different vascular mechanisms and changes in the brain. Some traditional Chinese herbal medicines were developed for treating VD. DH: Yizhi capsule is one such herbal concoction which is reported to improve clinical symptoms significantly. The efficacy and adverse effects of Yizhi capsule need to be reviewed systematically and assessed critically to inform clinical practice and guide the continued search for new treatment regimens. Objectives To assess the effectiveness and possible adverse events of 'Yizhi capsule' in treating vascular dementia. Search strategy The Cochrane Dementia and Cognitive Improvement Group's Specialised Register was searched on 18 September 2006 using the terms yi-zhi, "yi zhi" and yizhi. This database contains trial references from major health care databases and ongoing trial database and is up to date. In addition the review authors searched a variety of Chinese databases. Selection criteria Randomised, placebo controlled trials in which patients with vascular dementia were treated with 'Yizhi capsule' were included. Data collection and analysis Two authors independently assessed trial quality and extracted data. We telephoned study authors for missing information as to whether treatment allocation was randomised and other methodological details. Main results No studies were found that met the inclusion criteria. We identified nine references to trials which included the term 'Yizhi capsule' in the description of the interventions. Two study authors were contacted by telephone and we discovered that the allocation methods they had used were not actually randomised. Four references were describing the same study. Three studies were excluded because 'positive drugs' were used as a control. Authors' conclusions There is no evidence from randomised controlled trials to support or proscribe against the use of 'Yizhi capsule' as a treatment for vascular dementia.
14 citations
Patent•
4 Apr 2007
TL;DR: A Chinese medicine 'Yizhi capsule' for improving memory power and treating insomnia and hypomnesia is prepared from 6 Chinese-medicinal materials including walnut kernel, longan, pueraria root, wolfberry fruit, etc through pulverizing, granulating, mixing and loading in capsules as mentioned in this paper.
Abstract: A Chinese medicine 'Yizhi capsule' for improving memory power and treating insomnia and hypomnesia is prepared from 6 Chinese-medicinal materials including walnut kernel, longan, pueraria root, wolfberry fruit, etc through pulverizing, granulating, mixing and loading in capsules. It is rich in nutrients including amino acids, vitamins, phosphatide, polyose, protein, etc. Its preparing process is also disclosed.
8 citations
Patent•
18 Sep 2002
TL;DR: In this article, a capsule for invigorating function of brain and improving memory power is prepared from perilla seed and celery seed through extracting oil and proportioning. But its advantages are no EPA, and containing DHA.
Abstract: A "Yizhi" capsule for invigorating function of brain and improving memory power is prepared from perilla seed and celery seed through extracting oil and proportioning. Its advantages are no EPA, and containing DHA.
8 citations
Journal Article•
TL;DR: Yizhi capsule (YZC) was used in treating senile dementia as discussed by the authors, and the effect of YZC on balance and gait ability of vascular dementia patients was evaluated.
Abstract: OBJECTIVE To assess the efficacy of Yizhi capsule (YZC) in treating senile dementia. METHODS Sixty-one vascular dementia (VaD) patients were randomly divided into YZC and control groups. There were 32 cases in YZC group, 4 capsules each time three times a day. In control group, there were 29 cases, 2 mg of hydergine were given each time three times a day, single-blind method was used and the treatment course was two months. RESULTS YZC could remarkably increase mini-mental state examination (MMSE) and Hamilton Depression Scale (HDS) marks of VaD patients. YZC had the effect of improving balance and gait ability of VaD patients. YZC could improve the abnormal blood velocity (BV), as well as improve cerebral blood flow, brain electrical activity monitoring (BEAM) and hemorheological indexes especially for the abnormal case. No side-effect or toxic-effect was observed in the administration period. CONCLUSION YZC had certain effect on senile VaD, and it was safe in application.
7 citations
Journal Article•
TL;DR: Fufang Congrong Yizhi Capsule can reduce the level of MARCKS mRNA in hippocampus of old dementia rats caused by β-amyloid, through which it can improve the learning and memory function of the dementia old rats.
Abstract: Objective:To observe the effect of Fufang Congrong Yizhi Capsule on myristoylated alanine-rich C-kinase substrate (MARCKS) mRNA level in hippocampus of old dementia rats induced by β-amyloid(1-40). Methods: Animals were divided randomly into young group, old group, sham operation group, model group, western medicine group and Chinese medicine group. Model, western and Chinese medicine groups received β-amyloid (1-40) intracerebroventrical injection to build dementia animal model, and then Chinese and westein medicine groups received Fufang Congrong Yizhi Capsule and donepezil for 14 days, respectively. To observe changes of behavior and MARCKS mRNA under the effect of Chinese and western medicine by Morris test and RT-PCR test. Results: Learning and memory function of Chinese and western medicine groups were better than that of model group. MARCKS mRNA of model group was increased significantly, that of Chinese medicine group was decreased compared with model group. Conclusion: Fufang Congrong Yizhi Capsule can reduce the level of MARCKS mRNA in hippocampus of old dementia rats caused by β-amyloid(1-40), through which it can improve the learning and memory function of the dementia old rats.
5 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2015 | 1 |
| 2013 | 2 |
| 2010 | 1 |
| 2007 | 2 |
| 2006 | 1 |
| 2004 | 1 |